Advanced searches left 3/3

Metastatic Neuroendocrine Tumors - Springer Nature

Summarized by Plex Scholar
Last Updated: 20 February 2022

* If you want to update the article please login/register

Cushing’s syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine tumor of unknown primary origin: a case report and literature review

Case report A 43-year-old male patient presented with clinical signs consistent with Cushing's syndrome and adrenocortic hormone-dependent hypercortisolemia in a 43-year-old male patient. Despite a suspicious lesion on pituitary MRI, the high-dose dexamethasone suppression test and bilateral inferior petrosal sinus sampling findings were not compatible with Cushing's disease. In the thorax CT of the patient, who also had a history of COVID-19 infection, no tumorular lesion was present, but no tumor lesion was found. Multiple metastatic foci were established in mediastinal and hilar lymph nodes and the axial skeleton when 68Ga-SSTR PET/CT and 18FDG-PET/CT were carried out. UPO NEN is a controversial case, with ECS and confounding factors, such as previous infection and incidental lesions, influencing the diagnosis process. Even though radiologically undetectable, the case in question highlighted the fact that a common pulmonary carcinoid with a low proliferation index could cause visible metastases even when radiologically undetectable.

Source link: https://doi.org/10.1007/s42000-021-00316-z


Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy

Purpose: After peptide receptor radionuclide therapy, patients with neuroendocrine tumor liver metastases can have additional tumor reduction by sequential therapy with [166Ho]-radioembolization. The aim of this research was to investigate hemotoxic profiles, as well as the prognostic value of neutrophil-to-lymphocyte ratio and thrombocyte-to-lymphocyte ratio. Methods All patients who were included in the prospective HEPAR PLuS study were included in this research. To determine the prognostic value of NLR and TLR on response, logistic regression was used. Thirty-one patients were included in the toxicology analysis; thirty were included in the response analysis; thirty were not included in the response analysis. Patients in grade 3–4 lymphocyte toxicity were toxicity of ten patients. An increase in NLR and TLR at 3 weeks, compared to baseline, with a significant response at 3 months and at 6 months. At a 3-weeks follow-up, changes in NLR and TLR may be useful early predictors of response.

Source link: https://doi.org/10.1186/s13550-022-00880-4

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions